Literature DB >> 16638390

Treatment of limited extent extramammary Paget's disease with 5 percent imiquimod cream.

Christy Badgwell1, Ted Rosen.   

Abstract

Extramammary Paget's disease (EMPD) is a rare neoplastic condition of apocrine gland-bearing skin, which may be associated with internal malignancy. Although surgical excision is the generally accepted standard of care for EMPD, treatment with topical imiquimod 5 percent cream has reportedly been efficacious in clearing lesions. We report the case of a 78-year-old woman with biopsy-proven EMPD of the thigh treated successfully with imiquimod application thrice weekly for 16 weeks.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16638390

Source DB:  PubMed          Journal:  Dermatol Online J        ISSN: 1087-2108


  5 in total

1.  Extramammary Paget's disease of the scrotum with complete response to imiquimod and photodynamic therapy.

Authors:  Tyler M Bauman; Ilana S Rosman; David M Sheinbein
Journal:  BMJ Case Rep       Date:  2018-03-05

Review 2.  Effects of imiquimod on vulvar Paget's disease: a systematic review of literature.

Authors:  Hiroko Machida; Aida Moeini; Lynda D Roman; Koji Matsuo
Journal:  Gynecol Oncol       Date:  2015-07-17       Impact factor: 5.482

3.  Long-term functional and quality of life outcomes of patients after repair of large perianal skin defects for Paget's and Bowen's disease.

Authors:  Alissa Conklin; Imran Hassan; Heidi K Chua; E Dawn Wietfeldt; Dirk R Larson; Kristine A Thomsen; Sanhat Nivatvongs
Journal:  J Gastrointest Surg       Date:  2009-02-18       Impact factor: 3.452

4.  Mammary and extramammary Paget's disease: a study of 14 cases and the associated therapeutic difficulties.

Authors:  Vanessa D Andretta Tanaka; Jose Antonio Sanches; Luis Torezan; Ane Beatriz Niwa; Cyro Festa Neto
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

5.  Management of Extramammary Paget's Disease: A Case Report and Review of the Literature.

Authors:  Rosa Guerra; Subhasis Misra
Journal:  Case Rep Dermatol Med       Date:  2013-11-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.